Pharmaceutical - Cardio-vascular, Diabetes

Filter

Current filters:

Cardio-vascularDiabetes

Popular Filters

1 to 25 of 28 results

Boehringer Ingelheim gets two drugs approved by Scotland’s health watchdog

14-10-2014

The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following…

Boehringer IngelheimCardio-vascularDiabetesJardiancePharmaceuticalPradaxaPricingUK

Call for Indian govt to bring more essential drugs under price control from NGOs

Call for Indian govt to bring more essential drugs under price control from NGOs

22-08-2014

Non-governmental organizations in India have jointly issued a letter calling on the country’s government…

Cardio-vascularDiabetesIndiaNational Pharmaceuticals Pricing AuthorityPharmaceuticalPoliticsPricing

Six new drugs recommended for approval by EMA’s CHMP

Six new drugs recommended for approval by EMA’s CHMP

27-06-2014

At its end-June meetings, the European Medicines Agency’s Committee for Medicinal Products for Human…

AbasriaAnti-viralsBristol-Myers SquibbCardio-vascularDaklinzaDiabetesEli LillyEuropeFreseniusGE HealthcarePharmaceuticalRegulationTriumeqVelphoroVifor PharmaVizamyl

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

Ligand licenses five programs to Viking Therapeutics

23-05-2014

US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan

09-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment

26-09-2013

French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Akrikhin expands deal with Merck & Co

08-08-2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Sanofi plans acceleration of expansion into Ukraine this year

07-05-2013

French drug major Sanofi (Euronext: SAN) is considering expanding its presence in Ukraine this year,…

Cardio-vascularDiabetesEuropeMarkets & MarketingPharmaceuticalProductionSanofi

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes

11-03-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes…

BiotechnologyCardio-vascularDiabetesGilead SciencesPharmaceuticalRanexaResearch

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development

14-11-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

Market for regenerative medicine set to reach $1.4 billion in 2012; report

12-09-2012

The overall global market for translational regenerative medicine will reach a value of $1.4 billion…

BiotechnologyCardio-vascularDiabetesGlobalMarkets & MarketingOncologyPharmaceutical

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa

28-05-2012

Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received…

Boehringer IngelheimCardio-vascularDiabetesEli LillyEuropeJentaduetoPharmaceuticalPradaxaRegulation

1 to 25 of 28 results

Back to top